CCM
CALT

CAAS Capital Management’s Calliditas Therapeutics AB American Depositary Shares CALT Stock Holding History

CAAS Capital Management’s Portfolio CALT Stock Details CALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-25,000
Closed -$580K – 633
2020
Q2 		$580K Buy
+25,000
New +$495K 0.02% 303

Other funds holding CALT

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

CAAS Capital Management's CALT Position: Q3 2020 in Review

CAAS Capital Management sold out of Calliditas Therapeutics AB American Depositary Shares (CALT) in Q3 2020, closing a stake of 25,000 shares — an estimated $580K sold.

CAAS Capital Management first reported a position in CALT in Q2 2020 and held it in 1 quarter. The position peaked at $580K in Q2 2020. 16 funds tracked by Wall St. Rank hold CALT as of Q3 2020.

  • CAAS Capital Management reported no remaining Calliditas Therapeutics AB American Depositary Shares position as of Q3 2020 after selling out during the quarter.
  • CAAS Capital Management sold 25,000 Calliditas Therapeutics AB American Depositary Shares shares in Q3 2020, an estimated $580K.
  • CAAS Capital Management first reported a position in Calliditas Therapeutics AB American Depositary Shares in Q2 2020 and held it in 1 quarter.
  • CAAS Capital Management's Calliditas Therapeutics AB American Depositary Shares position peaked at $580K in Q2 2020.
  • 16 funds tracked by Wall St. Rank held Calliditas Therapeutics AB American Depositary Shares as of Q3 2020.

Based on CAAS Capital Management's 13F filing for Q3 2020, filed 9 Nov 2020.